XTRA:MRKPharmaceuticals
Will Flat 2026 Guidance and a Steady Dividend Change Merck KGaA's (XTRA:MRK) Investment Narrative?
In March 2026, Merck KGaA reported that its fourth-quarter 2025 sales slipped to €5,248.6 million and net income declined to €319.2 million, while full-year 2025 sales were broadly flat at €21.10 billion with net income of €2.61 billion, and it guided 2026 group net sales to €20–€21.10 billion, implying an organic sales change of about 1% decline to 2% growth.
The company also proposed maintaining a stable €2.20 dividend at its April 24 Annual General Meeting, highlighting an emphasis on...